Results 71 to 80 of about 1,470 (198)

Clinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disorders

Orphanet Journal of Rare Diseases
Background Neuromyelitis Optica Spectrum Disorders (NMOSD) comprise a group of autoimmune-mediated, inflammatory, demyelinating central nervous system diseases caused by aquaporin-4 (AQP4) IgG autoantibodies.
Wenjing Yang, Pei Chen, Jiaxuan Guo, Huiyu Feng, Xin Huang   +4 more
doaj   +1 more source

Resolution of anti-GAD-associated autoimmune encephalitis in patients treated with efgartigimod

Frontiers in Neurology
IntroductionTemporal lobe epilepsy (TLE) is a significant clinical phenotype of anti-glutamic acid decarboxylase (GAD)-associated disease, which is characterized by disturbances in GABAergic inhibitory neurotransmission.
Min Chen, Zhuajin Bi, Wenzhong Kang, Ruihan Liu, Liu Hongbo, Yan Jiang, Qun Wang, Qun Wang, Qun Wang   +8 more
doaj   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 796-806, April 2026.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies [PDF]

, 2020
PURPOSE OF REVIEW: To provide an update on immunomodulating and immunosuppressive therapies in myasthenia gravis and highlight newly approved, or pending approval, therapies with new biologics.
Dalakas, Marinos
core   +1 more source

Efgartigimod alfa for the treatment of primary immune thrombocytopenia

Therapeutic Advances in Hematology, 2023
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia. Most patients with ITP have antiplatelet antibodies of the immunoglobulin G (IgG) subtype which through interaction with platelet and megakaryocyte glycoproteins result in increased platelet destruction and inhibition of platelet ...
openaire   +3 more sources

Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany

European Journal of Neurology, Volume 33, Issue 4, April 2026.
C5‐inhibition may represent an effective adjunctive treatment in therapy‐refractory myasthenic crisis, including thymoma‐associated MG (TAMG). ABSTRACT Introduction Generalized myasthenia gravis (gMG) may progress to life‐threatening myasthenic crises (MC) requiring mechanical ventilation.
Lea Gerischer, Maike Stein, Alice Schneider, Hanna Tangen, Johanna Loris, Stefanie Glaubitz, Jana Zschüntzsch, Ulrich Hofstadt‐van Oy, Charlotte Schubert, Christoph Heesen, Melina Schlag, Tim Hagenacker, Menekse Oeztuerk, Tobias Ruck, Paolo Doksani, Carla Dusemund, Meret Herdick, Julia Herzig‐Nichtweiß, Philipp Mergenthaler, Frauke Stascheit, Amani Suboh, Lisa Schwarz, Sarah Hoffmann, Andreas Meisel, Sophie Lehnerer   +24 more
wiley   +1 more source

Double‐Filtration Plasmapheresis Versus Efgartigimod for Generalized Myasthenia Gravis: Severity‐Stratified Benefits in a Prospective Observational Multicenter Study

CNS Neuroscience &Therapeutics, Volume 32, Issue 3, March 2026.
Both Double‐Filtration Plasmapheresis (DFPP) and efgartigimod effectively treat acute exacerbations of generalized myasthenia gravis (gMG), with efficacy rising across successive sessions. In moderate‐to‐severe gMG, 3/5‐session DFPP outperformed 4‐infusion efgartigimod, while efficacy was comparable in mild cases.
Kan Wang, Hanyu Xin, Mengze Zhang, Qiuju Li, Yanan Wu, Xia Li, Jing Peng, Chong Xie, Xiajun Zhou, Li Gao, Xuzhong Pei, Yiwei Yang, Yuhui Wang, Yuan Zhong, Lu Zhang, Desheng Zhu, Yangtai Guan   +16 more
wiley   +1 more source

Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient‐Centric Treatment Goal

European Journal of Neurology, Volume 33, Issue 3, March 2026.
Conceptual framework supporting Minimal Symptom Expression (MSE) as a patient‐centric treatment goal in generalized myasthenia gravis. Guidelines prioritize minimal manifestations (MM) or better (MGFA‐PIS); MM is clinician‐judgment based and not instrument‐defined. MSE (MG‐ADL 0‐1) is standardized, actionable, and widely used. Across Phase III programs
Andreas Meisel, Akiyuki Uzawa, Cynthia Z. Qi, Dustin Nowacek, Jeff Guptill, James F. Howard Jr   +5 more
wiley   +1 more source

Characterizing Perinatal Treatment Patterns and Outcomes in Myasthenia Gravis

Muscle &Nerve, Volume 73, Issue 2, Page 269-276, February 2026.
ABSTRACT Introduction/Aims Studies on pregnancy in myasthenia gravis (MG) are limited by small sample sizes or examine a limited number of outcomes. The objective of this study was to estimate the prevalence of perinatal and infant outcomes and characterize perinatal treatment patterns in MG.
Melanie H. Jacobson, Rupa Makadia, Ashley E. L. Anderson, Zia Choudhry, Nathan Hall, Jill Hardin, Sicong Huang, Janice M. Massey, Anna Ostropolets, Ran Sun, Rebecca Zaha, Alexis A. Krumme   +11 more
wiley   +1 more source

Efgartigimodi alfa myasthenia graviksen hoidossa [PDF]

, 2022
Tämä arviointi käsittelee efgartigimodi alfaa standardihoitoon lisättynä asetyylikoliinireseptoripositiivisilla aikuispotilailla, joilla on yleistynyt myasthenia gravis.
Grönholm, Essi, Lamminsalo, Marko, Oravilahti, Tuomas   +2 more
core